These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 17960455)

  • 1. Is surgery indicated for patients with symptomatic nonfunctioning pancreatic neuroendocrine tumor and unresectable hepatic metastases?
    Hung JS; Chang MC; Lee PH; Tien YW
    World J Surg; 2007 Dec; 31(12):2392-7. PubMed ID: 17960455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors.
    Strosberg JR; Choi J; Cantor AB; Kvols LK
    Cancer Control; 2006 Jan; 13(1):72-8. PubMed ID: 16508629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of resection of the primary pancreatic neuroendocrine tumor in the multidisciplinary treatment of patients with unresectable synchronous liver metastases: a case series.
    Kondo NI; Ikeda Y; Maehara S; Sugimoto R; Nishiyama K; Sakaguchi Y
    JOP; 2013 Jul; 14(4):415-22. PubMed ID: 23846939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of pancreatic neuroendocrine tumors.
    Dickson PV; Behrman SW
    Surg Clin North Am; 2013 Jun; 93(3):675-91. PubMed ID: 23632152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic neuroendocrine metastases: does intervention alter outcomes?
    Chamberlain RS; Canes D; Brown KT; Saltz L; Jarnagin W; Fong Y; Blumgart LH
    J Am Coll Surg; 2000 Apr; 190(4):432-45. PubMed ID: 10757381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
    Caplin ME; Pavel M; Ćwikła JB; Phan AT; Raderer M; Sedláčková E; Cadiot G; Wolin EM; Capdevila J; Wall L; Rindi G; Langley A; Martinez S; Blumberg J; Ruszniewski P;
    N Engl J Med; 2014 Jul; 371(3):224-33. PubMed ID: 25014687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the role of primary tumour resection in patients with synchronous unresectable liver metastases from pancreatic neuroendocrine tumour of the body and tail. A propensity score survival evaluation.
    Bertani E; Fazio N; Radice D; Zardini C; Spinoglio G; Chiappa A; Ribero D; Biffi R; Partelli S; Falconi M
    Eur J Surg Oncol; 2017 Feb; 43(2):372-379. PubMed ID: 27742480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two-phase study of hepatic artery vascular occlusion with microencapsulated cisplatin in patients with liver metastases from neuroendocrine tumors.
    Diamandidou E; Ajani JA; Yang DJ; Chuang VP; Brown CA; Carrasco HC; Lawrence DD; Wallace S
    AJR Am J Roentgenol; 1998 Feb; 170(2):339-44. PubMed ID: 9456942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgical management of pancreatic neuroendocrine tumors.
    Kimura W; Tezuka K; Hirai I
    Surg Today; 2011 Oct; 41(10):1332-43. PubMed ID: 21922354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide.
    Ricci S; Antonuzzo A; Galli L; Ferdeghini M; Bodei L; Orlandini C; Conte PF
    Ann Oncol; 2000 Sep; 11(9):1127-30. PubMed ID: 11061606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic surgery for metastases from neuroendocrine tumors.
    Sarmiento JM; Que FG
    Surg Oncol Clin N Am; 2003 Jan; 12(1):231-42. PubMed ID: 12735141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Morbidity and mortality of aggressive resection in patients with advanced neuroendocrine tumors.
    Norton JA; Kivlen M; Li M; Schneider D; Chuter T; Jensen RT
    Arch Surg; 2003 Aug; 138(8):859-66. PubMed ID: 12912744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors.
    Ricci S; Antonuzzo A; Galli L; Orlandini C; Ferdeghini M; Boni G; Roncella M; Mosca F; Conte PF
    Am J Clin Oncol; 2000 Aug; 23(4):412-5. PubMed ID: 10955874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in survival for patients with resectable versus unresectable metastases from pancreatic islet cell cancer.
    House MG; Cameron JL; Lillemoe KD; Schulick RD; Choti MA; Hansel DE; Hruban RH; Maitra A; Yeo CJ
    J Gastrointest Surg; 2006 Jan; 10(1):138-45. PubMed ID: 16368504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multimodal Treatment of Vasoactive Intestinal Polypeptide-producing Pancreatic Neuroendocrine Tumors with Liver Metastases.
    Iwasaki M; Tsuchida K; Jinnai H; Komatsubara T; Arisaka T; Tsunemi M; Nakano M; Iijima M; Hiraishi H
    Intern Med; 2017; 56(5):517-522. PubMed ID: 28250297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant Capecitabine/Temozolomide for Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors.
    Squires MH; Worth PJ; Konda B; Shah MH; Dillhoff ME; Abdel-Misih S; Norton JA; Visser BC; Dua M; Pawlik TM; Schmidt CR; Poultsides G; Cloyd JM
    Pancreas; 2020 Mar; 49(3):355-360. PubMed ID: 32132509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
    Pavel ME; Phan AT; Wolin EM; Mirakhur B; Liyanage N; Pitman Lowenthal S; Fisher GA; Vinik AI;
    Oncologist; 2019 Apr; 24(4):463-474. PubMed ID: 30355775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant Treatment of Nonfunctioning Pancreatic Neuroendocrine Tumors with [177Lu-DOTA0,Tyr3]Octreotate.
    van Vliet EI; van Eijck CH; de Krijger RR; Nieveen van Dijkum EJ; Teunissen JJ; Kam BL; de Herder WW; Feelders RA; Bonsing BA; Brabander T; Krenning EP; Kwekkeboom DJ
    J Nucl Med; 2015 Nov; 56(11):1647-53. PubMed ID: 26272813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Two cases of neuroendocrine tumors of the pancreas with multiple liver metastases treated by use of degradable starch microspheres and octreotide].
    Goto W; Shimizu S; Kotsuka M; Sakae M; Kanazawa A; Tsukamoto T; Yamashita Y; Nishiguchi Y
    Gan To Kagaku Ryoho; 2014 Nov; 41(12):2139-41. PubMed ID: 25731449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Staged surgery with neoadjuvant 90Y-DOTATOC therapy for down-sizing synchronous bilobular hepatic metastases from a neuroendocrine pancreatic tumor.
    Stoeltzing O; Loss M; Huber E; Gross V; Eilles C; Mueller-Brand J; Schlitt HJ
    Langenbecks Arch Surg; 2010 Feb; 395(2):185-92. PubMed ID: 19506898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.